May 19, 2020 / 01:10PM GMT
Michael Leuchten - UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research
So good morning, good afternoon, everybody. My name is Michael Leuchten, pharma -- I'm one of the pharma analysts at UBS in London. Welcome to this fireside set with Roche. It's my pleasure to have CEO, Severin Schwan, with us on the line as well as Karl Mahler, Head of IR.
Severin's going to make some opening remarks, and then we're going to jump into Q&A. There is an ability for you to submit questions if you want to that I can see on the screen. If we have some time, I'm more than happy to circle back to them. But without further ado, Severin, over to you.
Severin Schwan - Roche Holding AG - CEO & Executive Director
Thank you, Michael. I'll keep it very short on my end so that we can quickly go into your questions.
You have seen Q1 results with plus 7%, and that's really very much the result of the new product launches, which continue to overcompensate for the biosimilar erosion. Obviously, we have also been very much
Roche Holding AG at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers